Literature DB >> 25695220

MiR-205 and MiR-375 microRNA assays to distinguish squamous cell carcinoma from adenocarcinoma in lung cancer biopsies.

Santosh Patnaik1, Reema Mallick, Eric Kannisto, Rohit Sharma, Wiam Bshara, Sai Yendamuri, Samjot Singh Dhillon.   

Abstract

INTRODUCTION: Identification of adenocarcinoma (AC) and squamous cell carcinoma (SCC) histology of non-small-cell lung cancer (NSCLC) in biopsies is clinically important but can be inaccurate by routine histopathologic examination. We quantify this inaccuracy at a cancer center, and evaluate the utility of a microRNA-based method to histotype AC/SCC in biopsies.
METHODS: RNA was extracted from tissue sections with greater than 90% tumor content that were macro- or micro-dissected from formalin-fixed, paraffin-embedded biopsy specimens. MicroRNAs in RNA from the biopsies and from resected tumors were quantified by TaqMan reverse transcription-polymerase chain reaction assays and normalized against the RNU6B housekeeping RNA. Publicly available microRNA expression datasets were examined.
RESULTS: NSCLC subtyping of small biopsy specimens by routine histopathologic examination either failed or mistyped the histology of 21% of 190 cases. Using 77 resectates, an reverse transcription-polymerase chain reaction-based assay of microRNAs miR-21, miR-205, and miR-375 was developed to identify AC and SCC subtypes of NSCLC. This method identified the AC/SCC histotypes of 25 biopsies with an accuracy of 96%, and correctly histotyped all 12 cases for which the histology had been mistyped by routine histopathologic examination of the biopsy. Examination of publicly available datasets identified miR-205 and miR-375 as microRNAs with the best ability to histotype AC and SCC, and that levels of the two microRNAs in AC or SCC are unaffected by the pathologic stage of the tumor or the age or race of the patient.
CONCLUSIONS: Histotypic microRNA assays can aid the subtyping of NSCLC biopsies as AC or SCC by standard histopathologic methods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695220      PMCID: PMC5819754          DOI: 10.1097/JTO.0000000000000423

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  39 in total

1.  A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens.

Authors:  Diana Montezuma; Rosa Azevedo; Paula Lopes; Renata Vieira; Ana Luísa Cunha; Rui Henrique
Journal:  Virchows Arch       Date:  2013-10-15       Impact factor: 4.064

2.  Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

Authors:  Natasha Rekhtman; Suzanne M Brandt; Carlie S Sigel; Maria A Friedlander; Gregory J Riely; William D Travis; Maureen F Zakowski; Andre L Moreira
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

3.  Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.

Authors:  Koji Tsuta; Yuko Tanabe; Akihiko Yoshida; Fumiaki Takahashi; Akiko M Maeshima; Hisao Asamura; Hitoshi Tsuda
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

4.  Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

Authors:  Natasha Rekhtman; Daphne C Ang; Camelia S Sima; William D Travis; Andre L Moreira
Journal:  Mod Pathol       Date:  2011-05-27       Impact factor: 7.842

5.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.

Authors:  Mi Jin Kim; Hyeong Chan Shin; Kyeong Cheol Shin; Jae Y Ro
Journal:  Ann Diagn Pathol       Date:  2012-10-04       Impact factor: 2.090

7.  MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.

Authors:  Charalambos C Solomides; Barry J Evans; Jean-Marc Navenot; Rajanikanth Vadigepalli; Stephen C Peiper; Zi-xuan Wang
Journal:  Acta Cytol       Date:  2012-11-24       Impact factor: 2.319

Review 8.  Intricacies of bevacizumab-induced toxicities and their management.

Authors:  Sarah M Gressett; Sachin R Shah
Journal:  Ann Pharmacother       Date:  2009-03-03       Impact factor: 3.154

9.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

10.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

View more
  19 in total

1.  Rebuttal from Dr. Mino-Kenudson.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2016-08

2.  Essential role of microRNA-650 in the regulation of B-cell CLL/lymphoma 11B gene expression following transplantation: A novel mechanism behind the acute rejection of renal allografts.

Authors:  Peng Jin; Hongxi Chen; Jinliang Xie; Cheng Zhou; Xiangrong Zhu
Journal:  Int J Mol Med       Date:  2017-10-17       Impact factor: 4.101

3.  MicroRNA-375 targets PAX6 and inhibits the viability, migration and invasion of human breast cancer MCF-7 cells.

Authors:  Qiongyan Zou; Wenjun Yi; Jianghai Huang; Fenfen Fu; Gannong Chen; Dewu Zhong
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

4.  [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].

Authors:  Shuxian Peng; Xun Li; Qin Liu; Yingheng Zhang; Liming Zou; Xiaoli Gong; Miaomiao Wang; Xiaodong Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-06-30

5.  Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.

Authors:  Xinzhong Zhu; Di Dong; Zhendong Chen; Mengjie Fang; Liwen Zhang; Jiangdian Song; Dongdong Yu; Yali Zang; Zhenyu Liu; Jingyun Shi; Jie Tian
Journal:  Eur Radiol       Date:  2018-02-15       Impact factor: 5.315

6.  Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?

Authors:  Erik Vassella; Stephanie Langsch; Matthias S Dettmer; Cornelia Schlup; Maja Neuenschwander; Milo Frattini; Mathias Gugger; Stephan C Schäfer
Journal:  Oncotarget       Date:  2015-09-15

7.  MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer.

Authors:  Jing-Hua Li; Shan-Shan Sun; Ning Li; Peng Lv; Shu-Yang Xie; Ping-Yu Wang
Journal:  Oncotarget       Date:  2017-08-14

8.  MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4.

Authors:  Hongxia Zhang; Xiaoning Zhang; Xiaoying Yuan; Linna Wang; Ying Xiao
Journal:  Iran J Basic Med Sci       Date:  2015-10       Impact factor: 2.699

9.  A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Hui Li; Zhengran Jiang; Qixin Leng; Fan Bai; Juan Wang; Xiaosong Ding; Yuehong Li; Xianghong Zhang; HongBin Fang; Harris G Yfantis; Lingxiao Xing; Feng Jiang
Journal:  Oncotarget       Date:  2017-04-11

Review 10.  microRNAs Make the Call in Cancer Personalized Medicine.

Authors:  Simone Detassis; Margherita Grasso; Valerio Del Vescovo; Michela A Denti
Journal:  Front Cell Dev Biol       Date:  2017-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.